J Refract Surg. 2023 Sep;39(9):589-596. doi: 10.3928/1081597X-20230726-02. Epub 2023 Sep 1.
To assess the clinical and aberrometric outcomes of a new Implantable Collamer Lens (EVO Viva ICL; STAAR Surgical) to correct moderate to high myopia and presbyopia.
The study included 80 eyes of 40 patients who had bilateral EVO Viva ICL implantation. Uncorrected (UDVA) and corrected (CDVA) distance visual acuities, refraction, presbyopic add power, binocular through-focus visual acuity, total ocular spherical aberration (SA), coma aberration, and root mean square of ocular higher order aberrations (RMS HOAs) (i-Trace Aberrometer; Tracey Technologies) for a 4.5-mm pupil size were evaluated.
The mean binocular postoperative UDVA and CDVA were 0.09 ± 0.19 and 0.02 ± 0.03 logMAR, respectively. The postoperative spherical equivalent was -0.61 ± 0.54 diopters (D). The presbyopic add power reduced from +1.31 ± 0.74 D preoperatively to +0.44 ± 0.58 D after surgery ( < .0001). The mean visual acuity was 0.1 logMAR or better (20/25 or better) across the vergence range from +0.50 to -1.50 D, better than 0.2 logMAR (20/32 or better) up to the vergence of -2.00 D, and remained better than 0.3 logMAR (20/40 or better) up to the vergence of -2.50 D. The total ocular aberrations induced by EVO Viva ICL were -0.34 ± 0.09 µm of SA, 0.24 ± 0.18 µm of coma, and 0.26 ± 0.12 µm of RMS HOAs.
The outcomes support that the new ICL might be a good alternative for myopia and presbyopia correction in patients aged between 45 and 55 years. Further studies are needed to evaluate the threshold lens misalignment from which the patient´s visual quality would be affected. .
评估新型可植入 Collamer 透镜(EVO Viva ICL;STAAR Surgical)矫正中高度近视和老视的临床和像差结果。
该研究纳入了 40 名患者的 80 只眼,这些患者均接受了双侧 EVO Viva ICL 植入术。评估了未矫正(UDVA)和矫正(CDVA)远距视力、屈光度、老视附加光度、双眼全程焦点视力、总眼球差(SA)、彗差和眼高阶像差均方根(RMS HOAs)(i-Trace 像差仪;Tracey Technologies)。瞳孔大小为 4.5mm。
双眼术后平均 UDVA 和 CDVA 分别为 0.09 ± 0.19 和 0.02 ± 0.03 logMAR。术后等效球镜度为-0.61 ± 0.54 屈光度(D)。术前老视附加光度为+1.31 ± 0.74 D,术后为+0.44 ± 0.58 D(<.0001)。在+0.50 至-1.50 D 的离焦范围内,平均视力为 0.1 logMAR 或更好(20/25 或更好),优于 0.2 logMAR(20/32 或更好)直至-2.00 D,且一直优于 0.3 logMAR(20/40 或更好)直至-2.50 D。EVO Viva ICL 引起的总眼像差为-0.34 ± 0.09 µm 的 SA、0.24 ± 0.18 µm 的彗差和 0.26 ± 0.12 µm 的 RMS HOAs。
结果支持新型 ICL 可能成为 45 至 55 岁近视和老视患者矫正的良好选择。需要进一步的研究来评估可能影响患者视觉质量的阈值晶状体偏心。